Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Enterprise Value (2016 - 2025)

Guided Therapeutics' Enterprise Value history spans 16 years, with the latest figure at -$63000.0 for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 83.76% to -$63000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$63000.0, a 83.76% increase, with the full-year FY2025 number at -$63000.0, up 83.76% from a year prior.
  • Enterprise Value hit -$63000.0 in Q4 2025 for Guided Therapeutics, up from -$87000.0 in the prior quarter.
  • Over the last five years, Enterprise Value for GTHP hit a ceiling of -$63000.0 in Q4 2025 and a floor of -$2.7 million in Q3 2022.
  • Historically, Enterprise Value has averaged -$790150.0 across 5 years, with a median of -$566000.0 in 2021.
  • Biggest five-year swings in Enterprise Value: crashed 5838.1% in 2021 and later skyrocketed 83.76% in 2025.
  • Tracing GTHP's Enterprise Value over 5 years: stood at -$643000.0 in 2021, then tumbled by 259.72% to -$2.3 million in 2022, then surged by 74.45% to -$591000.0 in 2023, then surged by 34.35% to -$388000.0 in 2024, then skyrocketed by 83.76% to -$63000.0 in 2025.
  • Business Quant data shows Enterprise Value for GTHP at -$63000.0 in Q4 2025, -$87000.0 in Q3 2025, and -$185000.0 in Q2 2025.